Study guide
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities
Key Takeaways Explain This Topic AI
Tobacco use remains the single largest modifiable cause of cancer death in the United States and is causally linked to at least 12 malignancies, not lung cancer alone.
Infectious agents account for a substantial share of global cancer burden: HPV drives nearly all cervical and most oropharyngeal cancers, hepatitis B and C drive hepatocellular carcinoma, H. pylori drives gastric adenocarcinoma and MALT lymphoma, and EBV drives nasopharyngeal carcinoma and some lymphomas.
Black Americans have the highest overall cancer death rate of any racial or ethnic group in the United States, with the widest absolute gaps in prostate, breast, and colorectal cancer mortality.
Sexual and gender minority patients face documented screening deficits, and organ-based inventory rather than recorded gender determines which screening tests are indicated.
Occupational and environmental carcinogens with established causal links include asbestos (mesothelioma, lung), benzene (acute myeloid leukemia), radon (lung), aromatic amines (bladder), and ionizing radiation (leukemia, thyroid, breast).
Last updated: August 2026
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities
Blueprint focus: ONCC Domain I.A.1 — At-risk populations, including disparities in culture, socioeconomic status, age, LGBTQIA status, gender identity, occupations, medical history, and geographic location. Expect stems that ask which patient is at greatest risk, which exposure explains a malignancy, or which barrier best explains a late-stage diagnosis.
Why Risk Stratification Comes First
Screening recommendations, genetic referral thresholds, and surveillance intervals all key off risk category. An advanced practice nurse who cannot place a patient into average, increased, or high risk cannot correctly apply any downstream guideline. Risk assessment is also where equity enters oncology practice: two patients with identical biology can have very different outcomes because one had a mammogram at 42 and the other first presented to an emergency department with a fungating mass.
Cancer risk factors divide into three broad tiers.
Non-modifiable host factors — age, biological sex, race and ancestry, height, and inherited germline variants.
Modifiable behavioral and metabolic factors — tobacco, alcohol, obesity, physical inactivity, diet, ultraviolet exposure, and hormone use.
Environmental, occupational, and infectious exposures — asbestos, radon, benzene, ionizing radiation, and oncogenic pathogens.
Age is the dominant single risk factor. Incidence rises steeply after age 50 for most epithelial cancers because carcinogenesis requires the accumulation of multiple somatic mutations. This is why almost every average-risk screening guideline begins in midlife, and why a malignancy diagnosed well below the guideline age should prompt a hereditary risk assessment.
Modifiable Behavioral and Metabolic Risk
Exposure Malignancies with established causal association Practice point
Tobacco (smoked and smokeless) Lung, larynx, oral cavity, pharynx, esophagus, stomach, pancreas, liver, kidney, bladder, cervix, colorectum, acute myeloid leukemia Largest modifiable cause of cancer death; risk falls measurably within 5 years of cessation but never returns fully to never-smoker baseline
Alcohol Oral cavity, pharynx, larynx, esophagus (squamous), liver, colorectum, female breast Risk is dose-dependent with no established safe threshold for breast cancer; synergistic with tobacco in the aerodigestive tract
Excess adiposity Endometrial, postmenopausal breast, colorectal, kidney, esophageal adenocarcinoma, pancreas, liver, gastric cardia, ovary, thyroid, meningioma, multiple myeloma Adipose aromatase raises circulating estrogen; insulin resistance and chronic inflammation add independent effects
Physical inactivity Colon, breast, endometrium Meeting 150 minutes/week of moderate activity is a Category 1 recommendation in survivorship as well as prevention
Ultraviolet radiation Melanoma, basal and squamous cell carcinoma Intermittent intense exposure and indoor tanning carry the strongest melanoma signal
Combined menopausal hormone therapy Breast Estrogen-plus-progestin raises breast cancer risk; estrogen alone after hysterectomy does not carry the same signal
Infectious Carcinogens
Roughly one in six cancers worldwide is attributable to an infectious agent, and several are directly preventable.
Human papillomavirus (HPV) — causes virtually all cervical cancer and the majority of oropharyngeal, anal, vaginal, vulvar, and penile squamous carcinomas. HPV-positive oropharyngeal cancer is staged separately from tobacco-related disease because its prognosis is markedly better.
Hepatitis B and C — hepatocellular carcinoma. Chronic carriers require surveillance ultrasound with or without alpha-fetoprotein every 6 months.
Helicobacter pylori — gastric adenocarcinoma and gastric MALT lymphoma. Eradication alone can induce remission in localized MALT lymphoma.
Epstein-Barr virus (EBV) — nasopharyngeal carcinoma, Burkitt lymphoma, post-transplant lymphoproliferative disorder, and a subset of Hodgkin lymphoma and gastric cancers.
Human herpesvirus 8 (HHV-8) — Kaposi sarcoma and primary effusion lymphoma.
HIV — an immunosuppressive amplifier of the AIDS-defining malignancies (Kaposi sarcoma, aggressive non-Hodgkin lymphoma, cervical cancer) and of anal and lung cancer risk.
Occupational, Environmental, and Iatrogenic Exposures
Take an occupational history when the histology or age of onset does not fit the patient's behavioral profile.
Asbestos — mesothelioma (latency commonly 20 to 40 years) and lung cancer, multiplicatively increased by concurrent smoking. Shipyard, insulation, construction, and brake work.
Radon — the second-leading cause of lung cancer in the United States; risk depends on home foundation and geography.
Benzene — acute myeloid leukemia and myelodysplastic syndrome. Petrochemical work, rubber manufacturing, painting.
Aromatic amines and polycyclic aromatic hydrocarbons — urothelial carcinoma. Dye, rubber, leather, and firefighting exposures.
Ionizing radiation — leukemia, thyroid, and breast cancer; risk is highest with childhood or adolescent exposure and rises with cumulative dose.
Prior cytotoxic therapy — alkylating agents and topoisomerase II inhibitors cause therapy-related myeloid neoplasms; this is covered in detail in the survivorship and second-primary sections.
Disparities: Culture, Socioeconomic Status, Identity, and Geography
The blueprint names these explicitly, so treat them as testable content rather than background.
Race and ancestry. Black Americans carry the highest overall cancer mortality rate of any US racial or ethnic group. Black men have roughly double the prostate cancer death rate of White men, and Black women die of breast cancer at a substantially higher rate than White women despite similar or lower incidence — a gap driven predominantly by later stage at diagnosis, longer time to treatment initiation, and higher rates of triple-negative disease. American Indian and Alaska Native populations have elevated kidney, liver, and stomach cancer mortality. Ancestry also carries biological signal: founder BRCA1/2 variants are enriched in people of Ashkenazi Jewish ancestry, and BRCA2 -associated aggressive prostate cancer is more prevalent in men of African lineage.
Socioeconomic status and insurance. Uninsured and Medicaid-insured patients present at more advanced stage and have worse survival across nearly every tumor site. Cost-related medication non-adherence, transportation failure, inability to take unpaid leave, and low health literacy are all mediators the nurse practitioner can intervene on directly.
Sexual orientation and gender identity. Sexual and gender minority patients report lower rates of guideline-concordant screening, higher tobacco and alcohol use, and avoidance of care after prior discriminatory encounters. Two clinical rules follow. First, screen the organs the patient has , not the gender recorded in the chart: a transgender man who retains a cervix still needs cervical screening, and a transgender woman on long-term estrogen therapy needs an individualized breast screening discussion. Second, document an organ inventory at intake so that the screening plan does not depend on any clinician's assumption.
Geography. Rural residents face longer travel distances, fewer oncology subspecialists, lower clinical trial availability, and higher mortality from lung, colorectal, and cervical cancer. Appalachian and Deep South regions carry persistently elevated cervical and lung cancer mortality that tracks with screening access rather than with biology.
Medical history as a risk modifier. Inflammatory bowel disease raises colorectal risk in proportion to disease duration and extent; chronic immunosuppression after solid organ transplant multiplies skin cancer and post-transplant lymphoproliferative disorder risk; Barrett esophagus, atypical ductal hyperplasia, lobular carcinoma in situ, and monoclonal gammopathy of undetermined significance are all precursor states with their own surveillance obligations.
APRN Assessment Workflow
Take a three-generation family history and update it at least annually — new relative diagnoses change referral eligibility.
Quantify tobacco exposure in pack-years and record the quit date, because both figures gate lung cancer screening eligibility.
Record an organ inventory and prior surgical history rather than relying on recorded sex or gender.
Screen for social drivers : transportation, housing stability, food security, insurance status, caregiving obligations, and health literacy.
Convert findings into an explicit risk category , then apply the matching screening pathway and, if criteria are met, refer for genetic counseling.